Figure 3: MBH PKC-δ activation and VLDL-TG secretion.

Experimental protocol shown in Fig. 2b. Independent groups received adenoviral injection of LacZ or DN PKC-δ immediately following stereotaxic surgery as indicated. (a) Plasma TG concentrations and (b) rates of appearance of VLDL-TG in plasma in rats with prior adenoviral LacZ injection with MBH infusion of vehicle (white open squares, n=5) or oleic acid (black squares, n=6) or adenoviral DN PKC-δ injection with MBH infusion of vehicle (grey circles, n=6 or oleic acid (grey triangles, n=6). *P<0.05 versus other groups. (c) Plasma TG concentrations and (d) rates of appearance of VLDL-TG in plasma with MBH infusion of rot (white open squares, n=5), OAG (black squares, n=5), OAG+rot (grey circles, n=6) and in rats with prior adenoviral LacZ injection with OAG (dark grey triangles, n=7) or adenoviral DN PKC-δ injection with OAG (light grey triangles, n=5). *P<0.01 OAG versus rot, OAG+rot; †P<0.05 LacZ+OAG versus DN PKC-δ+OAG. Data are presented as mean+s.e.m. Statistical significance determined by Dunnett’s post hoc test after analysis of variance (ANOVA). For measurements over time, repeated measures ANOVA was used followed by Duncan’s post hoc test.